A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis

Daratumumab is a human monoclonal antibody targeting CD38, an antigen uniformly expressed by plasma cells in multiple myeloma and light-chain amyloidosis (AL). We report the results of a prospective multicenter phase 2 study of daratumumab monotherapy in AL (NCT02816476). Forty previously treated AL...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2020-04, Vol.135 (18), p.1531-1540
Hauptverfasser: Roussel, Murielle, Merlini, Giampaolo, Chevret, Sylvie, Arnulf, Bertrand, Stoppa, Anne Marie, Perrot, Aurore, Palladini, Giovanni, Karlin, Lionel, Royer, Bruno, Huart, Antoine, Macro, Margaret, Morel, Pierre, Frenzel, Laurent, Touzeau, Cyrille, Boyle, Eileen, Dorvaux, Véronique, Le Bras, Fabien, Lavergne, David, Bridoux, Frank, Jaccard, Arnaud
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Daratumumab is a human monoclonal antibody targeting CD38, an antigen uniformly expressed by plasma cells in multiple myeloma and light-chain amyloidosis (AL). We report the results of a prospective multicenter phase 2 study of daratumumab monotherapy in AL (NCT02816476). Forty previously treated AL patients with a difference between involved and uninvolved free light chains (dFLC) >50 mg/L were included in 15 centers between September of 2016 and April of 2018. Patients received 6 28-day cycles of IV daratumumab, every week for cycles 1 and 2 and every 2 weeks for cycles 3 through 6. Median age was 69 years (range, 45-83). Twenty-six patients had ≥2 organs involved, with heart in 24 and kidney in 26. Median time from diagnosis to enrollment was 23 months (interquartile range, 4-122), with a median of 3 prior therapies (range, 1-5). At data cutoff (September of 2019), all patients discontinued therapy; 33 received the planned 6 cycles. Overall, 22 patients had hematological response, and 19 patients (47.5%) achieved very good partial response (dFLC
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.2019004369